{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:16:09Z","timestamp":1787318169645,"version":"build-2736575974"},"reference-count":74,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Fondo de Investigaci\u00f3n Sanitaria, Instituto de Salud Carlos III, Madrid, Spain","doi-asserted-by":"publisher","award":["RETICS RD16\/0006\/0004"],"award-info":[{"award-number":["RETICS RD16\/0006\/0004"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Fondo de Investigaci\u00f3n Sanitaria, Instituto de Salud Carlos III, Madrid, Spain","doi-asserted-by":"publisher","award":["PI18\/00540"],"award-info":[{"award-number":["PI18\/00540"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Fondo de Investigaci\u00f3n Sanitaria, Instituto de Salud Carlos III, Madrid, Spain","doi-asserted-by":"publisher","award":["PI21\/01683"],"award-info":[{"award-number":["PI21\/01683"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Fondo de Investigaci\u00f3n Sanitaria, Instituto de Salud Carlos III, Madrid, Spain","doi-asserted-by":"publisher","award":["IB20134"],"award-info":[{"award-number":["IB20134"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Fondo de Investigaci\u00f3n Sanitaria, Instituto de Salud Carlos III, Madrid, Spain","doi-asserted-by":"publisher","award":["GR21073"],"award-info":[{"award-number":["GR21073"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Junta de Extremadura, Madrid, Spain","award":["RETICS RD16\/0006\/0004"],"award-info":[{"award-number":["RETICS RD16\/0006\/0004"]}]},{"name":"Junta de Extremadura, Madrid, Spain","award":["PI18\/00540"],"award-info":[{"award-number":["PI18\/00540"]}]},{"name":"Junta de Extremadura, Madrid, Spain","award":["PI21\/01683"],"award-info":[{"award-number":["PI21\/01683"]}]},{"name":"Junta de Extremadura, Madrid, Spain","award":["IB20134"],"award-info":[{"award-number":["IB20134"]}]},{"name":"Junta de Extremadura, Madrid, Spain","award":["GR21073"],"award-info":[{"award-number":["GR21073"]}]},{"name":"FEDER funds","award":["RETICS RD16\/0006\/0004"],"award-info":[{"award-number":["RETICS RD16\/0006\/0004"]}]},{"name":"FEDER funds","award":["PI18\/00540"],"award-info":[{"award-number":["PI18\/00540"]}]},{"name":"FEDER funds","award":["PI21\/01683"],"award-info":[{"award-number":["PI21\/01683"]}]},{"name":"FEDER funds","award":["IB20134"],"award-info":[{"award-number":["IB20134"]}]},{"name":"FEDER funds","award":["GR21073"],"award-info":[{"award-number":["GR21073"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Coenzyme Q10 (CoQ10) has an important role as an antioxidant. Being that oxidative stress is one of the mechanisms involved in the pathogenesis of Parkinson\u2019s disease (PD) and other neurodegenerative diseases, several studies addressed the concentrations of CoQ10 in the different tissues of patients with PD and other parkinsonian syndromes (PS), trying to elucidate their value as a marker of these diseases. Other studies addressed the potential therapeutic role of CoQ10 in PD and PS. We underwent a systematic review and a meta-analysis of studies measuring tissue CoQ10 concentrations which shows that, compared with controls, PD patients have decreased CoQ10 levels in the cerebellar cortex, platelets, and lymphocytes, increased total and oxidized CoQ10 levels in the cerebrospinal fluid and a non-significant trend toward decreased serum\/plasma CoQ10 levels. Patients with multiple system atrophy (MSA) showed decreased CoQ10 levels in the cerebellar cortex, serum\/plasma, cerebrospinal fluid, and skin fibroblasts. Patients with Lewy body dementia (LBD) showed decreased cerebellar cortex CoQ10, and those with progressive supranuclear palsy (PSP) had decreased CoQ10 levels in the cerebrospinal fluid. A previous meta-analysis of studies addressing the therapeutic effects of CoQ10 in PD showed a lack of improvement in patients with early PD. Results of the treatment with CoQ10 in PSP should be considered preliminary. The potential role of CoQ10 therapy in the MSA and selected groups of PD patients deserves future studies.<\/jats:p>","DOI":"10.3390\/jpm12060975","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T03:01:22Z","timestamp":1655348482000},"page":"975","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Coenzyme Q10 and Parkinsonian Syndromes: A Systematic Review"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7558-7323","authenticated-orcid":false,"given":"F\u00e9lix Javier","family":"Jim\u00e9nez-Jim\u00e9nez","sequence":"first","affiliation":[{"name":"Section of Neurology, Hospital Universitario del Sureste, Ronda del Sur 10, E28500 Arganda del Rey, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hortensia","family":"Alonso-Navarro","sequence":"additional","affiliation":[{"name":"Section of Neurology, Hospital Universitario del Sureste, Ronda del Sur 10, E28500 Arganda del Rey, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Garc\u00eda-Mart\u00edn","sequence":"additional","affiliation":[{"name":"ARADyAL Instituto de Salud Carlos III, University Institute of Molecular Pathology Biomarkers, Universidad de Extremadura, E10071 C\u00e1ceres, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6895-9160","authenticated-orcid":false,"given":"Jos\u00e9 A. G.","family":"Ag\u00fandez","sequence":"additional","affiliation":[{"name":"ARADyAL Instituto de Salud Carlos III, University Institute of Molecular Pathology Biomarkers, Universidad de Extremadura, E10071 C\u00e1ceres, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/07315724.2001.10719063","article-title":"Biochemical functions of coenzyme Q10","volume":"20","author":"Crane","year":"2001","journal-title":"J. Am. Coll. Nutr."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Mantle, D., Heaton, R.A., and Hargreaves, I.P. (2021). Coenzyme Q10, Ageing and the Nervous System, An Overview. Antioxidants, 11.","DOI":"10.3390\/antiox11010002"},{"key":"ref_3","first-page":"425","article-title":"Mecanismos patog\u00e9nicos de la enfermedad de Parkinson","volume":"Volume 1","author":"Luquin","year":"2008","journal-title":"Tratado de los Trastornos del Movimiento"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Jurcau, A. (2021). Insights into the Pathogenesis of Neurodegenerative Diseases, Focus on Mitochondrial Dysfunction and Oxidative Stress. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111847"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., and Group, P. (2009). Preferred reporting items for systematic reviews and meta-analyses, the PRISMA statement. PLoS Med., 6.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"ref_6","unstructured":"Wells, G.A., Shea, B., O\u2019Connell, D., Peterson, J., Welch, V., Losos, M., and Tugwell, P. (2022, May 10). The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta analyses. Available online: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology, a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2009","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: A practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s007020070050","article-title":"Serum levels of coenzyme Q10 in patients with Parkinson\u2019s disease","volume":"107","author":"Molina","year":"2000","journal-title":"J. Neural. Transm."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.nbd.2003.10.003","article-title":"Plasma and CSF markers of oxidative stress are increased in Parkinson\u2019s disease and influenced by antiparkinsonian medication","volume":"15","author":"Buhmann","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jns.2004.05.007","article-title":"Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson\u2019s disease","volume":"223","author":"Sohmiya","year":"2004","journal-title":"J. Neurol. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7754\/Clin.Lab.2015.150538","article-title":"A Panel of Oxidative Stress Markers in Parkinson\u2019s Disease","volume":"62","author":"Bolner","year":"2016","journal-title":"Clin. Lab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12017-012-8174-1","article-title":"Coenzyme Q10, hyperhomocysteinemia and MTHFR C677T polymorphism in levodopa-treated Parkinson\u2019s disease patients","volume":"14","author":"Gorgone","year":"2012","journal-title":"Neuromolecular Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Kasai, T., Tokuda, T., Ohmichi, T., Ishii, R., Tatebe, H., Nakagawa, M., and Mizuno, T. (2016). Serum Levels of Coenzyme Q10 in Patients with Multiple System Atrophy. PLoS One, 11.","DOI":"10.1371\/journal.pone.0147574"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.parkreldis.2018.07.017","article-title":"Clinical correlates of decreased plasma coenzyme Q10 levels in patients with multiple system atrophy","volume":"57","author":"Du","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s007020050003","article-title":"Altered redox state of platelet coenzyme Q10 in Parkinson\u2019s disease","volume":"107","author":"Gerstner","year":"2000","journal-title":"J. Neural. Transm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jns.2012.03.023","article-title":"Coenzyme Q10 deficiency in patients with Parkinson\u2019s disease","volume":"318","author":"Mischley","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jocn.2005.12.023","article-title":"Increase of oxidized\/total coenzyme Q-10 ratio in cerebrospinal fluid in patients with Parkinson\u2019s disease","volume":"14","author":"Isobe","year":"2007","journal-title":"J. Clin. Neurosci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.parkreldis.2017.10.010","article-title":"Cerebrospinal fluid levels of coenzyme Q10 are reduced in multiple system atrophy","volume":"46","author":"Compta","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.neulet.2008.09.069","article-title":"The coenzyme Q10 status of the brain regions of Parkinson\u2019s disease patients","volume":"447","author":"Hargreaves","year":"2008","journal-title":"Neurosci Lett."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Schottlaender, L.V., Bettencourt, C., Kiely, A.P., Chalasani, A., Neergheen, V., Holton, J.L., Hargreaves, I., and Houlden, H. (2016). Coenzyme Q10 Levels Are Decreased in the Cerebellum of Multiple-System Atrophy Patients. PLoS One, 11.","DOI":"10.1371\/journal.pone.0149557"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/jnen\/nlw037","article-title":"Decreased Coenzyme Q10 Levels in Multiple System Atrophy Cerebellum","volume":"75","author":"Barca","year":"2016","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Del Hoyo, P., Garc\u00eda-Redondo, A., de Bustos, F., Molina, J.A., Sabed, Y., Alonso-Navarro, H., Caballero, L., Arenas, J., Ag\u00fandez, J.A., and Jim\u00e9nez-Jim\u00e9nez, F.J. (2010). Oxidative stress in skin fibroblasts cultures from patients with Parkinson\u2019s disease. BMC Neurol., 10.","DOI":"10.1186\/1471-2377-10-95"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/jamaneurol.2016.1325","article-title":"Plasma Coenzyme Q10 Levels in Patients With Multiple System Atrophy","volume":"73","author":"Mitsui","year":"2016","journal-title":"JAMA Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1016\/j.bbadis.2018.09.018","article-title":"Mitochondrial dysfunction in fibroblasts of Multiple System Atrophy","volume":"1864","author":"Compagnoni","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00702-001-0761-5","article-title":"Serum levels of coenzyme Q in patients with Lewy body disease","volume":"109","author":"Molina","year":"2002","journal-title":"J. Neural. Transm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000319452","article-title":"Oxidative imbalance in different neurodegenerative diseases with memory impairment","volume":"8","author":"Gironi","year":"2011","journal-title":"Neurodegener. Dis."},{"key":"ref_28","unstructured":"Folkers, K., Littarru, G.P., and Yamagami, T. (1991). Serum coenzyme Q-10 level in Parkinson syndrome. Biomedical and Clinical Aspects of Coenzyme Q, Elsevier Science."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1016\/S0098-2997(97)00008-3","article-title":"Q10 therapy in patients with idiopathic Parkinson\u2019s disease","volume":"18","author":"Strijks","year":"1997","journal-title":"Mol. Aspects Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/archneur.59.10.1541","article-title":"Effects of coenzyme Q10 in early Parkinson disease, evidence of slowing of the functional decline","volume":"59","author":"Shults","year":"2002","journal-title":"Arch. Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0304-3940(03)00185-X","article-title":"Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson\u2019s disease","volume":"341","author":"Gholipour","year":"2003","journal-title":"Neurosci. Lett."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"NINDS NET-PD Investigators (2007). A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology, 68, 20\u201328.","DOI":"10.1212\/01.wnl.0000250355.28474.8e"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/archneur.64.7.nct60005","article-title":"Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease","volume":"64","author":"Storch","year":"2007","journal-title":"Arch. Neurol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group QE3 Investigators, Beal, M.F., Oakes, D., Shoulson, I., Henchcliffe, C., Galpern, W.R., Haas, R., Juncos, J.L., Nutt, J.G., and Voss, T.S. (2014). A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease, no evidence of benefit. JAMA Neurol., 71, 543\u2013552.","DOI":"10.1001\/jamaneurol.2014.131"},{"key":"ref_35","first-page":"79","article-title":"Clinical effects and safety of coenzyme Q10 in Parkinson disease","volume":"23","author":"Jie","year":"2014","journal-title":"China Foreign Med. Treat."},{"key":"ref_36","first-page":"151","article-title":"Clinical observation of coenzyme Q10 in Parkinson disease","volume":"36","author":"Wang","year":"2014","journal-title":"HeBei J. TCM"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000377676","article-title":"The effect of creatine and coenzyme q10 combination therapy on mild cognitive impairment in Parkinson\u2019s disease","volume":"73","author":"Li","year":"2015","journal-title":"Eur. Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.parkreldis.2015.05.022","article-title":"Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson\u2019s disease","volume":"21","author":"Yoritaka","year":"2015","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_39","first-page":"CD008150","article-title":"Coenzyme Q10 for Parkinson\u2019s disease","volume":"12","author":"Liu","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2174\/1871527314666150821103306","article-title":"Coenzyme Q10 for Patients with Parkinson\u2019s Disease: A Systematic Review and Meta-Analysis","volume":"15","author":"Negida","year":"2016","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10072-016-2757-9","article-title":"The efficacy and safety of coenzyme Q10 in Parkinson\u2019s disease: A meta-analysis of randomized controlled trials","volume":"38","author":"Zhu","year":"2017","journal-title":"Neurol. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12311-017-0846-9","article-title":"Three-Year Follow-Up of High-Dose Ubiquinol Supplementation in a Case of Familial Multiple System Atrophy with Compound Heterozygous COQ2 Mutations","volume":"16","author":"Mitsui","year":"2017","journal-title":"Cerebellum."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/mds.22023","article-title":"Short-term effects of coenzyme Q10 in progressive supranuclear palsy: A randomized, placebo-controlled trial","volume":"23","author":"Stamelou","year":"2008","journal-title":"Mov. Disord."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Apetauerova, D., Scala, S.A., Hamill, R.W., Simon, D.K., Pathak, S., Ruthazer, R., Standaert, D.G., and Yacoubian, T.A. (2016). CoQ10 in progressive supranuclear palsy: A randomized, placebo-controlled, double-blind trial. Neurol. Neuroimmunol. Neuroinflamm., 3.","DOI":"10.1212\/NXI.0000000000000266"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/biof.5520090222","article-title":"Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases","volume":"9","author":"Beal","year":"1999","journal-title":"Biofactors"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/biof.5520090223","article-title":"A possible role of coenzyme Q10 in the etiology and treatment of Parkinson\u2019s disease","volume":"9","author":"Shults","year":"1999","journal-title":"Biofactors"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0006-8993(97)01192-X","article-title":"Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1.;2.;3.; Tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice","volume":"783","author":"Beal","year":"1998","journal-title":"Brain Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1111\/j.1471-4159.2007.05097.x","article-title":"Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism","volume":"104","author":"Cleren","year":"2008","journal-title":"J. Neurochem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10072-011-0627-z","article-title":"Oral administration of coenzyme Q10 reduces MPTP-induced loss of dopaminergic nerve terminals in the striatum in mice","volume":"33","author":"Kobayashi","year":"2012","journal-title":"Neurol. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3389\/fncel.2018.00529","article-title":"Idebenone Alleviates Neuroinflammation and Modulates Microglial Polarization in LPS-Stimulated BV2 Cells and MPTP-Induced Parkinson\u2019s Disease Mice","volume":"12","author":"Yan","year":"2019","journal-title":"Front. Cell. Neurosci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1210\/en.2003-0163","article-title":"Coenzyme Q induces nigral mitochondrial uncoupling and prevents dopamine cell loss in a primate model of Parkinson\u2019s disease","volume":"144","author":"Horvath","year":"2003","journal-title":"Endocrinology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/j.1471-4159.2009.06074.x","article-title":"Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson\u2019s and Huntington\u2019s diseases","volume":"109","author":"Yang","year":"2009","journal-title":"J. Neurochem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0014-4886(95)90033-0","article-title":"Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity","volume":"132","author":"Schulz","year":"1995","journal-title":"Exp. Neurol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1007\/s11011-021-00795-4","article-title":"Neuroprotective effects of coenzyme Q10 in Parkinson\u2019s model via a novel Q10\/miR-149-5p\/MMPs pathway","volume":"36","author":"Ghasemloo","year":"2021","journal-title":"Metab. Brain Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.pathophys.2011.05.004","article-title":"BMSC and CoQ10 improve behavioural recovery and histological outcome in rat model of Parkinson\u2019s disease","volume":"18","author":"Nezhadi","year":"2011","journal-title":"Pathophysiology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1385\/JMN:28:2:125","article-title":"Coenzyme Q(10) provides neuroprotection in iron-induced apoptosis in dopaminergic neurons","volume":"28","author":"Kooncumchoo","year":"2006","journal-title":"J. Mol. Neurosci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/FBP.0000000000000342","article-title":"Neuroprotective effects of coenzyme Q10 on paraquat-induced Parkinson\u2019s disease in experimental animals","volume":"29","author":"Attia","year":"2018","journal-title":"Behav. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1471-2202-10-88","article-title":"Paraquat induces oxidative stress.; Neuronal loss in substantia nigra region and parkinsonism in adult rats, neuroprotection and amelioration of symptoms by water-soluble formulation of coenzyme Q10","volume":"10","author":"Sandhu","year":"2009","journal-title":"BMC Neurosci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.taap.2011.07.015","article-title":"Protection of dichlorvos induced oxidative stress and nigrostriatal neuronal death by chronic coenzyme Q10 pretreatment","volume":"256","author":"Binukumar","year":"2011","journal-title":"Toxicol Appl. Pharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.neuropharm.2008.08.033","article-title":"Mechanism of the neuroprotective role of coenzyme Q10 with or without L-dopa in rotenone-induced parkinsonism","volume":"55","author":"Abdin","year":"2008","journal-title":"Neuropharmacology."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s11064-020-03186-w","article-title":"Idebenone Ameliorates Rotenone-Induced Parkinson\u2019s Disease in Rats Through Decreasing Lipid Peroxidation","volume":"46","author":"Yavuz","year":"2021","journal-title":"Neurochem. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1471-4159.2005.03112.x","article-title":"Mitochondrial membrane depolarization and the selective death of dopaminergic neurons by rotenone, protective effect of coenzyme Q10","volume":"93","author":"Moon","year":"2005","journal-title":"J. Neurochem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.taap.2004.04.019","article-title":"Paraquat induces oxidative stress and neuronal cell death; neuroprotection by water-soluble Coenzyme Q10","volume":"201","author":"McCarthy","year":"2004","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s11064-020-03033-y","article-title":"The Effect of Organophosphate Exposure on Neuronal Cell Coenzyme Q10 Status","volume":"46","author":"Turton","year":"2001","journal-title":"Neurochem. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2174\/1874609812666191023153724","article-title":"An Investigation of the Anti-Parkinsonism Potential of Co-enzyme Q10 and Co-enzyme Q10\/Levodopa-carbidopa Combination in Mice","volume":"14","author":"Onaolapo","year":"2021","journal-title":"Curr. Aging Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1089\/rej.2017.1959","article-title":"Attenuation of Oxidative Damage by Coenzyme Q10 Loaded Nanoemulsion Through Oral Route for the Management of Parkinson\u2019s Disease","volume":"21","author":"Gupta","year":"2018","journal-title":"Rejuvenation Res."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Faust, K., Gehrke, S., Yang, Y., Yang, L., Beal, M.F., and Lu, B. (2009). Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson\u2019s disease. BMC Neurosci., 10.","DOI":"10.1186\/1471-2202-10-109"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s12640-011-9245-z","article-title":"Idebenone induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells","volume":"20","author":"Tai","year":"2011","journal-title":"Neurotox. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0014-5793(99)01444-1","article-title":"1-Methyl-4-phenyl-2.;3-dihydropyridinium is transformed by ubiquinone to the selective nigrostriatal toxin 1-methyl-4-phenylpyridinium","volume":"461","author":"Shi","year":"1999","journal-title":"FEBS Lett."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0891-5849(95)02207-4","article-title":"The effect of ascorbate and ubiquinone supplementation on plasma and CSF total antioxidant capacity","volume":"21","author":"Ahonen","year":"1996","journal-title":"Free Radic. Biol. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.expneurol.2004.05.003","article-title":"Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson\u2019s disease","volume":"188","author":"Shults","year":"2004","journal-title":"Exp. Neurol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/biof.5520320125","article-title":"Blood CoQ10 levels and safety profile after single-dose or chronic administration of PureSorb-Q40, animal and human studies","volume":"32","author":"Nukui","year":"2008","journal-title":"Biofactors."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1089\/ars.2013.5801","article-title":"Does high-dose coenzyme Q10 improve oxidative damage and clinical outcomes in Parkinson\u2019s disease?","volume":"21","author":"Seet","year":"2014","journal-title":"Antioxid. Redox Signal."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s42466-019-0033-1","article-title":"An omics-based strategy using coenzyme Q10 in patients with Parkinson\u2019s disease, concept evaluation in a double-blind randomized placebo-controlled parallel group trial","volume":"1","author":"Prasuhn","year":"2019","journal-title":"Neurol. Res. Pract."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/6\/975\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:32:16Z","timestamp":1760139136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/6\/975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,15]]},"references-count":74,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["jpm12060975"],"URL":"https:\/\/doi.org\/10.3390\/jpm12060975","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,15]]}}}